title: Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms.
abstract: The treatment of severe mental illness, and of psychiatric disorders in general, is limited in its efficacy and tolerability. There appear to be substantial interindividual differences in response to psychiatric drug treatments that are generally far greater than the differences between individual drugs; likewise, the occurrence of adverse effects also varies profoundly between individuals. These differences are thought to reflect, at least in part, genetic variability. The action of psychiatric drugs primarily involves effects on synaptic neurotransmission; the genes for neurotransmitter receptors and transporters have provided strong candidates in pharmacogenetic research in psychiatry. This paper reviews some aspects of the pharmacogenetics of neurotransmitter receptors and transporters in the treatment of psychiatric disorders. A focus on serotonin, catecholamines and amino acid transmitter systems reflects the direction of research efforts, while relevant results from some genome-wide association studies are also presented. There are many inconsistencies, particularly between candidate gene and genome-wide association studies. However, some consistency is seen in candidate gene studies supporting established pharmacological mechanisms of antipsychotic and antidepressant response with associations of functional genetic polymorphisms in, respectively, the dopamine D2 receptor and serotonin transporter and receptors. More recently identified effects of genes related to amino acid neurotransmission on the outcome of treatment of schizophrenia, bipolar illness or depression reflect the growing understanding of the roles of glutamate and γ-aminobutyric acid dysfunction in severe mental illness. A complete understanding of psychiatric pharmacogenomics will also need to take into account epigenetic factors, such as DNA methylation, that influence individual responses to drugs.
authors.affiliation: Biomedical Research Centre, Sheffield Hallam University, Sheffield, UK.
authors.forename: Gavin P
authors.initials: GP
authors.lastname: Reynolds
authors.forename: Olga O
authors.initials: OO
authors.lastname: McGowan
authors.forename: Caroline F
authors.initials: CF
authors.lastname: Dalton
mesh_terms: D057890:Epigenomics; D059647:Gene-Environment Interaction; D056726:Genetic Association Studies; D055106:Genome-Wide Association Study; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy / Q000235:genetics*; D050479:Neurotransmitter Transport Proteins / Q000235:genetics*; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic / Q000235:genetics; D011619:Psychotropic Drugs / Q000627:therapeutic use; D017981:Receptors, Neurotransmitter / Q000235:genetics*
chemical_list: D050479:Neurotransmitter Transport Proteins; D011619:Psychotropic Drugs; D017981:Receptors, Neurotransmitter
keywords: antidepressant drugs; antipsychotic drugs; bipolar illness; depression; gene; schizophrenia